查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2129251

細胞外基質生物材料市場預測至2034年－全球分析（依生物材料來源、細胞外基質材料類型、材料形態、支架結構、功能特性、器官、加工技術、應用、最終用戶及地區分類）

Extracellular Matrix Biomaterials Market Forecasts To 2034 - Global Analysis By Biomaterial Source, ECM Material Type, Material Form, Scaffold Architecture, Functional Properties, Organ, Processing Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球細胞外基質生物材料市場規模將達到 5,210 萬美元，並在預測期內以 7.3% 的複合年成長率成長，到 2034 年將達到 9,160 萬美元。

細胞外基質（ECM）生物材料是指天然來源或人工合成的材料，其設計目的是複製組織內細胞周圍基質的結構、生物學和功能特性。這些材料包括膠原蛋白、彈性蛋白、纖維纖連蛋白、層黏連蛋白、Glico，以及透過組織去細胞法獲得的基質。 ECM生物材料透過為細胞黏附、增殖、遷移和分化創造有利環境，在組織工程、再生醫學、傷口護理和植入式醫療應用中發揮至關重要的作用。去細胞技術、材料加工和生物製造技術的進步正在提高其可重複性、安全性和臨床性能，同時更好地保留原始生物訊號。人們對再生醫學日益成長的興趣持續推動著基於ECM的生物材料技術的開發和應用。

對再生醫學的需求日益成長

再生醫學的廣泛應用顯著提升了對細胞外基質（ECM）生物材料的需求。 ECM生物材料能夠提供結構框架和生物訊號，從而促進細胞黏附、增殖、分化和組織修復。基於ECM的材料在傷口處理、組織重組、整形外科手術、心血管修復和其他再生醫學領域備受關注。由於這些材料能夠模擬天然組織環境的關鍵特性，因此它們為開發積極促進生物癒合的療法提供了一個極具前景的平台。醫療產業正從單純治療症狀轉向修復和再生受損組織，為ECM技術的發展創造了有利環境。因此，基於ECM的生物材料解決方案的探索、創新和商業化在全球範圍內持續推進。

高昂的製造和加工成本

細胞外基質（ECM）生物材料的製造成本相對較高，這仍然是市場發展的一大限制因素，尤其是源自生物組織的產品。製造過程可能需要組織來源、去細胞處理、純化、滅菌、儲存以及嚴格的品管程序。為了確保所有生產批次的結構和生物特性一致，營運成本還會進一步增加。一些先進的ECM產品可能需要專用設施或嚴格控制的生產環境來保護材料的完整性。這些成本使得預算緊張的中小型企業和醫療機構難以獲得這些生物材料。與許多傳統的合成替代品相比，高昂的製造成本會阻礙這些材料的廣泛應用。因此，簡化加工方法、提高生產效率以及開發可擴展的生產系統對於克服這些經濟障礙至關重要。

複合和混合生物材料技術的發展

混合生物材料的開發是拓展細胞外基質（ECM）應用範圍的另一個極具前景的途徑。透過將天然ECM成分與合成聚合物、陶瓷、水凝膠、奈米顆粒、生長因子和其他功能性材料結合，可以克服單一材料系統固有的缺陷。這種組合有望帶來更優異的機械性能、可調控的分解速率、增強的生物活性以及更佳的製造和操作特性。例如，將ECM成分整合到人工支架中，可以將天然基質的生物功能與合成材料的均勻性和可控性結合。這種混合平台可應用於整形外科重組、傷口護理、藥物傳遞、組織工程和再生醫學等領域。多功能材料的持續創新將促進差異化ECM產品的開發，並有助於拓展其未來的商業性潛力。

關於組織衍生性材料的倫理和社會問題

對人源和動物源性材料的倫理來源和使用的擔憂可能會對細胞外基質（ECM）生物材料的推廣應用構成挑戰。一些患者、臨床醫生、醫療機構或倡導團體可能會對組織捐贈、捐贈者知情同意、可追溯性、動物源性成分以及負責任的生物來源提出疑問。文化和社會觀點的差異也會影響國際市場的接受度。隨著公眾關注度的提高，監管機構和醫療機構可能會要求更高的透明度、更完善的文件記錄和更嚴格的來源控制。因此，製造商可能需要清晰地解釋其材料的來源，並建立全面的可追溯性系統和負責任的採購慣例。如果倫理方面的擔憂加劇，企業可能會面臨更高的遵循成本、某些生物來源原料的使用限制以及某些組織來源的ECM產品接受度的下降。

新型冠狀病毒（COVID-19）的影響：

新冠疫情對整個細胞外基質（ECM）生物材料領域造成了重大衝擊，影響了研究計畫、臨床試驗、實驗室運作和材料供應。醫療資源和研究重點轉向新冠疫情導致許多無關的臨床研究延期，生物材料供應鏈也面臨採購和運輸困難。然而，疫情也為ECM技術帶來了新的機遇，因為SARS-CoV-2病毒與組織和器官損傷有關，這凸顯了再生醫學方法的重要性。研究人員日益關注生物材料、支架、水凝膠和組織工程平台，以支持組織修復、藥物傳遞和再生。總而言之，儘管新冠疫情初期限制了市場活動，但隨後卻激發了人們對基於生物材料的再生醫學的研究興趣。

在預測期內，「動物源性」細分市場預計將佔據最大佔有率。

預計在預測期內，動物源性材料將佔據最大的市場佔有率，這得益於其在細胞外基質（ECM）生物材料開發領域悠久的應用歷史和豐富的來源。源自豬、牛和羊組織的材料能夠保留重要的細胞外基質結構和生物成分，以促進細胞間相互作用、組織修復和再生。其在傷口處理、軟組織重組、外科加強和再生醫學等領域的成熟應用記錄，使其在臨床實踐中得到廣泛認可。在這些來源中，豬組織特別重要，因為它來源相對豐富，並且能夠提供適用於多種生物醫學應用的結構特性。因此，動物源性ECM材料成熟的臨床應用、廣泛的來源和良好的生物功能，使其在市場中佔據主導地位。

預計在預測期內，「類器官開發」細分市場將呈現最高的複合年成長率。

在預測期內，「類器官開發」領域預計將呈現最高的成長率，這主要得益於類器官作為人體組織結構和功能高階模型的廣泛應用。基於細胞外基質（ECM）的材料能夠模擬支持細胞黏附、增殖、分化、組織和成熟的3D微環境。隨著生理代表性組織模型價值的日益凸顯，ECM材料在疾病建模、精準醫療、藥物研發和毒性評估等領域的應用也日益增加。幹細胞研究、3D細胞培養和生物工程技術的進步，推動了更先進、更可重複的類器官系統的開發。這些技術進步可望提升對ECM生物材料的需求，並加速其在類器官研發的應用。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其完善的醫療保健體系、強大的生物技術和醫療設備產業，以及在再生醫學領域的積極研究。基於細胞外基質（ECM）的解決方案在該地區廣泛應用於傷口管理、組織重組、外科修復和其他治療應用。強大的學術和研究基礎設施、不斷提高的臨床接受度以及對組織工程技術的持續投入，為市場擴張創造了有利條件。美國憑藉其先進的醫療保健基礎設施、廣泛的生物醫學研究生態系統以及ECM生物材料在再生和重組醫學領域不斷擴展的應用，成為該地區的主要貢獻者。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於再生醫學研究的拓展、醫療基礎設施的改善以及先進生物材料技術的進步。中國、日本、韓國和印度等國家正在加強其生物技術和組織工程能力，從而促進了基於細胞外基質（ECM）產品的更廣泛應用。對組織重組、ECM水凝膠、支架、 3D細胞培養和生物製造的需求不斷成長，也推動了該地區的成長。預計研發投入的增加、技術的進步以及再生醫學解決方案的商業化將進一步加速市場發展。這些趨勢為ECM生物材料開發公司創造了極具吸引力的機遇，鞏固了亞太地區作為成長最快區域市場的地位。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性評估）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章：全球細胞外基質生物材料市場：依原料分類

  • 人類來源
  • 動物源性
  • 植物來源
  • 微生物來源
  • 重組與合成

第6章 全球細胞外基質生物材料市場：依細胞外基質材料類型分類

  • 膠原蛋白
  • 彈性蛋白
  • 纖連蛋白
  • 層黏連蛋白
  • 玻尿酸
  • 纖維蛋白
  • 蛋白聚醣
  • 去細胞細胞外基質

第7章 全球細胞外基質生物材料市場：依材料形式分類

  • 水凝膠
  • 鷹架
  • 片材和膜
  • 海綿
  • 電影
  • 注射用生物材料
  • 微粒和奈米顆粒
  • 生物墨水

第8章：全球細胞外基質生物材料市場：依支架結構分類

  • 多孔
  • 纖維狀的
  • 奈米結構
  • 複合材料
  • 坡度

第9章 全球細胞外基質生物材料市場：依功能特性分類

  • 細胞黏附
  • 細胞誘導
  • 可生物分解
  • 生物活性
  • 免疫調節作用
  • 血管新生
  • 骨誘導
  • 自組織類型

第10章 全球細胞外基質生物材料市場：依器官分類

  • 皮膚
  • 骨骼和軟骨
  • 心血管系統
  • 神經系統
  • 肌肉
  • 肝
  • 腎
  • 肺
  • 角膜和眼睛
  • 牙科和口腔健康

第11章 全球細胞外基質生物材料市場：依加工技術分類

  • 去細胞化
  • 溶解
  • 橋
  • 冷凍乾燥
  • 靜電紡絲
  • 3D生物列印
  • 凝膠化
  • 化學改性
  • 酵素處理

第12章 全球細胞外基質生物材料市場：依應用分類

  • 組織工程
  • 創傷治療
  • 藥物輸送
  • 細胞療法
  • 基因遞送
  • 3D細胞培養
  • 類器官的發育
  • 疾病模型
  • 藥物篩檢和毒理學

第13章 全球細胞外基質生物材料市場：依最終使用者分類

  • 製藥和生物技術公司
  • 醫療設備製造商
  • 醫院和診所
  • 學術和研究機構
  • 受託研究機構

第14章 全球細胞外基質生物材料市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第15章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第16章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第17章：公司簡介

  • Integra LifeSciences Corporation
  • AbbVie Inc.（Allergan Aesthetics）
  • LifeNet Health
  • MTF Biologics
  • Organogenesis Holdings Inc.
  • CollPlant Biotechnologies Ltd.
  • Matricel GmbH
  • Cook Biotech Inc.
  • Stryker Corporation
  • Smith+Nephew plc
  • CorMatrix Cardiovascular, Inc.
  • Tissue Regenix Group plc
  • Miromatrix Medical Inc.
  • AxoGen, Inc.
  • Humacyte, Inc.
  • Kerecis
  • RTI Surgical Holdings, Inc.
  • Medtronic plc
Product Code: SMRC39364

According to Stratistics MRC, the Global Extracellular Matrix Biomaterials Market is accounted for $52.1 million in 2026 and is expected to reach $91.6 million by 2034 growing at a CAGR of 7.3% during the forecast period. Extracellular matrix (ECM) biomaterials comprise natural or engineered materials developed to reproduce the structural, biological, and functional properties of the matrix that surrounds cells within tissues. They may contain collagen, elastin, fibronectin, laminin, glycosaminoglycans, or matrices obtained through tissue decellularization. By creating favorable conditions for cellular attachment, growth, movement, and differentiation, ECM biomaterials have become important in tissue engineering, regenerative medicine, wound treatment, and implantable medical applications. Improvements in decellularization techniques, material processing, and biofabrication are enabling better preservation of native biological cues while improving reproducibility, safety, and clinical performance. Increasing interest in regenerative healthcare continues to drive the development and utilization of ECM-based biomaterial technologies.

Market Dynamics:

Driver:

Increasing Demand for Regenerative Medicine

The expanding use of regenerative medicine is significantly supporting demand for extracellular matrix (ECM) biomaterials. Their ability to provide structural frameworks and biological cues encourages cellular attachment, growth, differentiation, and tissue restoration. ECM-based materials are gaining attention across wound management, tissue reconstruction, orthopedic procedures, cardiovascular repair, and other regenerative applications. Because these materials can reproduce important characteristics of natural tissue environments, they offer promising platforms for developing therapies that actively support biological healing. The healthcare industry's increasing emphasis on repairing or regenerating damaged tissues instead of simply treating symptoms is creating favorable conditions for ECM technologies. Consequently, research, innovation, and commercialization of ECM-based biomaterial solutions continue to expand globally.\

Restraint:

High Manufacturing and Processing Costs

The relatively expensive production of ECM biomaterials remains a significant market constraint, especially for products obtained from biological tissues. Manufacturing may require tissue sourcing, decellularization, purification, sterilization, preservation, and extensive quality-control procedures. Ensuring that every production batch maintains comparable structural and biological characteristics can further increase operating costs. Some advanced ECM products also depend on specialized equipment and tightly controlled manufacturing environments to protect material integrity. Such expenses can make these biomaterials less accessible to smaller companies and healthcare organizations with restricted budgets. Compared with many conventional synthetic alternatives, higher manufacturing costs can therefore slow wider adoption. Streamlining processing methods, improving production yields, and developing scalable manufacturing systems will be essential for reducing these economic barriers.

Opportunity:

Expansion into Combination and Hybrid Biomaterial Technologies

Hybrid biomaterial development provides another promising avenue for expanding ECM applications. Natural ECM components can be integrated with synthetic polymers, ceramics, hydrogels, nanoparticles, growth factors, and other functional substances to overcome weaknesses associated with individual material systems. These combinations can potentially deliver stronger mechanical performance, adjustable degradation, enhanced biological activity, and improved manufacturing or handling properties. For instance, incorporating ECM components into engineered scaffolds can unite the biological functionality of natural matrices with the consistency and controllability of synthetic materials. Such hybrid platforms may serve orthopedic reconstruction, wound treatment, drug delivery, tissue engineering, and regenerative therapies. Ongoing innovation in multifunctional materials can help create differentiated ECM products and broaden their future commercial potential.

Threat:

Ethical and Public Concerns Regarding Tissue-Derived Materials

Concerns about the ethical sourcing and utilization of human- and animal-derived materials may create challenges for ECM biomaterial adoption. Certain patients, clinicians, institutions, or advocacy groups may question issues involving tissue donation, donor consent, traceability, animal-derived components, and responsible biological sourcing. Differences in cultural and social perspectives can also influence acceptance across international markets. Greater public attention may lead regulators and healthcare organizations to demand stronger transparency, documentation, and sourcing controls. Manufacturers may consequently need to develop comprehensive traceability systems and responsible sourcing practices while communicating clearly about material origins. If ethical concerns intensify, companies could face higher compliance expenses, restrictions on specific biological sources, and reduced acceptance of certain tissue-derived ECM products.

Covid-19 Impact:

The COVID-19 outbreak created considerable disruption across the ECM biomaterials sector, affecting research programs, clinical investigations, laboratory operations, and material availability. Numerous non-pandemic clinical studies experienced delays as healthcare resources and research priorities shifted toward COVID-19, while biological-material supply chains encountered sourcing and transportation difficulties. However, the pandemic also created new opportunities for ECM technologies because SARS-CoV-2 was associated with tissue and organ injuries that required potential regenerative approaches. Researchers increasingly examined biomaterials, scaffolds, hydrogels, and tissue-engineering platforms for supporting tissue repair, therapeutic delivery, and regeneration. Overall, COVID-19 initially constrained market activities but subsequently stimulated research interest in biomaterial-based regenerative applications.

The Animal-Derived segment is expected to be the largest during the forecast period

The Animal-Derived segment is expected to account for the largest market share during the forecast period, driven by its longstanding application and strong availability across ECM biomaterial development. Materials obtained from porcine, bovine, and ovine tissues can retain essential extracellular matrix structures and biological components that encourage cellular interaction, tissue repair, and regeneration. Their established applications in wound management, soft-tissue reconstruction, surgical reinforcement, and regenerative procedures have supported widespread clinical acceptance. Among these sources, porcine tissues are particularly important because they are comparatively abundant and can provide structural properties suitable for various biomedical applications. Consequently, the established clinical use, accessibility, and biological functionality of animal-derived ECM materials support their leading position.

The Organoid Development segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Organoid Development segment is predicted to witness the highest growth rate, supported by the expanding use of organoids as advanced models of human tissue structure and function. ECM-based materials can recreate supportive three-dimensional microenvironments that facilitate cellular attachment, growth, differentiation, organization, and maturation. Their use is increasing across disease modeling, precision medicine, pharmaceutical research, and toxicity assessment, where physiologically representative tissue models are increasingly valuable. Progress in stem-cell research, three-dimensional cell culture, and bioengineering is enabling the development of more sophisticated and reproducible organoid systems. These technological developments are expected to increase demand for ECM biomaterials and accelerate their adoption within organoid-based research and therapeutic development.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by well-developed healthcare systems, established biotechnology and medical-device industries, and significant research activity in regenerative medicine. The region has witnessed broad utilization of ECM-based solutions for wound management, tissue reconstruction, surgical repair, and other therapeutic applications. Strong academic and research infrastructure, increasing clinical acceptance, and continued investment in tissue-engineering technologies are creating favorable conditions for market expansion. The United States is a key regional contributor due to its advanced medical infrastructure, extensive biomedical research ecosystem, and growing application of ECM biomaterials in regenerative and reconstructive healthcare.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by expanding regenerative medicine research, improving healthcare infrastructure, and increasing development of advanced biomaterial technologies. Countries including China, Japan, South Korea, and India are strengthening their biotechnology and tissue-engineering capabilities, encouraging wider adoption of ECM-based products. Rising demand for tissue reconstruction, ECM hydrogels, scaffolds, three-dimensional cell culture, and biofabrication is also contributing to regional growth. Increasing research investments, technological advancements, and the commercialization of regenerative healthcare solutions are expected to further accelerate market development. These trends are creating attractive opportunities for ECM biomaterial developers and supporting Asia Pacific's position as the fastest-growing regional market.

Key players in the market

Some of the key players in Extracellular Matrix Biomaterials Market include Integra LifeSciences Corporation, AbbVie Inc. (Allergan Aesthetics), LifeNet Health, MTF Biologics, Organogenesis Holdings Inc., CollPlant Biotechnologies Ltd., Matricel GmbH, Cook Biotech Inc., Stryker Corporation, Smith+Nephew plc, CorMatrix Cardiovascular, Inc., Tissue Regenix Group plc, Miromatrix Medical Inc., AxoGen, Inc., Humacyte, Inc., Kerecis, RTI Surgical Holdings, Inc. and Medtronic plc.

Key Developments:

In March 2026, Smith+Nephew and the Pro Football Hall of Fame announced an extension of their strategic partnership through 2028. Smith+Nephew will continue as the Hall's Official Joint Replacement and Sports Medicine Partner, with activities focused on connecting patients with healthcare providers and promoting joint-health solutions.

In February 2026, Integra announced a new Chief Technology Officer position and stated that the role would strengthen its innovation pipeline through organic and partnership efforts, including identifying emerging technologies and opportunities for future growth.

Biomaterial Sources Covered:

  • Human-Derived
  • Animal-Derived
  • Plant-Derived
  • Microbial-Derived
  • Recombinant and Synthetic

ECM Material Types Covered:

  • Collagen
  • Elastin
  • Fibronectin
  • Laminin
  • Hyaluronic Acid
  • Fibrin
  • Proteoglycans
  • Decellularized ECM

Material Forms Covered:

  • Hydrogels
  • Scaffolds
  • Sheets and Membranes
  • Sponges
  • Films
  • Injectable Biomaterials
  • Microparticles and Nanoparticles
  • Bioinks

Scaffold Architectures Covered:

  • Porous
  • Fibrous
  • Nanostructured
  • Composite
  • Gradient

Functional Properties Covered:

  • Cell-Adhesive
  • Cell-Instructive
  • Biodegradable
  • Bioactive
  • Immunomodulatory
  • Angiogenic
  • Osteoinductive
  • Self-Assembling

Organs Covered:

  • Skin
  • Bone and Cartilage
  • Cardiovascular
  • Neural
  • Muscle
  • Liver
  • Kidney
  • Lung
  • Corneal and Ocular
  • Dental and Oral

Processing Technologies Covered:

  • Decellularization
  • Solubilization
  • Crosslinking
  • Freeze-Drying
  • Electrospinning
  • 3D Bioprinting
  • Gelation
  • Chemical Modification
  • Enzymatic Processing

Applications Covered:

  • Tissue Engineering
  • Wound Healing
  • Drug Delivery
  • Cell Therapy
  • Gene Delivery
  • 3D Cell Culture
  • Organoid Development
  • Disease Modeling
  • Drug Screening and Toxicology

End Users Covered:

  • Pharmaceutical and Biotechnology Companies
  • Medical Device Companies
  • Hospitals and Clinics
  • Academic and Research Institutions
  • Contract Research Organizations

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Extracellular Matrix Biomaterials Market, By Biomaterial Source

  • 5.1 Human-Derived
  • 5.2 Animal-Derived
  • 5.3 Plant-Derived
  • 5.4 Microbial-Derived
  • 5.5 Recombinant and Synthetic

6 Global Extracellular Matrix Biomaterials Market, By ECM Material Type

  • 6.1 Collagen
  • 6.2 Elastin
  • 6.3 Fibronectin
  • 6.4 Laminin
  • 6.5 Hyaluronic Acid
  • 6.6 Fibrin
  • 6.7 Proteoglycans
  • 6.8 Decellularized ECM

7 Global Extracellular Matrix Biomaterials Market, By Material Form

  • 7.1 Hydrogels
  • 7.2 Scaffolds
  • 7.3 Sheets and Membranes
  • 7.4 Sponges
  • 7.5 Films
  • 7.6 Injectable Biomaterials
  • 7.7 Microparticles and Nanoparticles
  • 7.8 Bioinks

8 Global Extracellular Matrix Biomaterials Market, By Scaffold Architecture

  • 8.1 Porous
  • 8.2 Fibrous
  • 8.3 Nanostructured
  • 8.4 Composite
  • 8.5 Gradient

9 Global Extracellular Matrix Biomaterials Market, By Functional Properties

  • 9.1 Cell-Adhesive
  • 9.2 Cell-Instructive
  • 9.3 Biodegradable
  • 9.4 Bioactive
  • 9.5 Immunomodulatory
  • 9.6 Angiogenic
  • 9.7 Osteoinductive
  • 9.8 Self-Assembling

10 Global Extracellular Matrix Biomaterials Market, By Organ

  • 10.1 Skin
  • 10.2 Bone and Cartilage
  • 10.3 Cardiovascular
  • 10.4 Neural
  • 10.5 Muscle
  • 10.6 Liver
  • 10.7 Kidney
  • 10.8 Lung
  • 10.9 Corneal and Ocular
  • 10.10 Dental and Oral

11 Global Extracellular Matrix Biomaterials Market, By Processing Technology

  • 11.1 Decellularization
  • 11.2 Solubilization
  • 11.3 Crosslinking
  • 11.4 Freeze-Drying
  • 11.5 Electrospinning
  • 11.6 3D Bioprinting
  • 11.7 Gelation
  • 11.8 Chemical Modification
  • 11.9 Enzymatic Processing

12 Global Extracellular Matrix Biomaterials Market, By Application

  • 12.1 Tissue Engineering
  • 12.2 Wound Healing
  • 12.3 Drug Delivery
  • 12.4 Cell Therapy
  • 12.5 Gene Delivery
  • 12.6 3D Cell Culture
  • 12.7 Organoid Development
  • 12.8 Disease Modeling
  • 12.9 Drug Screening and Toxicology

13 Global Extracellular Matrix Biomaterials Market, By End User

  • 13.1 Pharmaceutical and Biotechnology Companies
  • 13.2 Medical Device Companies
  • 13.3 Hospitals and Clinics
  • 13.4 Academic and Research Institutions
  • 13.5 Contract Research Organizations

14 Global Extracellular Matrix Biomaterials Market, By Geography

  • 14.1 North America
    • 14.1.1 United States
    • 14.1.2 Canada
    • 14.1.3 Mexico
  • 14.2 Europe
    • 14.2.1 United Kingdom
    • 14.2.2 Germany
    • 14.2.3 France
    • 14.2.4 Italy
    • 14.2.5 Spain
    • 14.2.6 Netherlands
    • 14.2.7 Belgium
    • 14.2.8 Sweden
    • 14.2.9 Switzerland
    • 14.2.10 Poland
    • 14.2.11 Rest of Europe
  • 14.3 Asia Pacific
    • 14.3.1 China
    • 14.3.2 Japan
    • 14.3.3 India
    • 14.3.4 South Korea
    • 14.3.5 Australia
    • 14.3.6 Indonesia
    • 14.3.7 Thailand
    • 14.3.8 Malaysia
    • 14.3.9 Singapore
    • 14.3.10 Vietnam
    • 14.3.11 Rest of Asia Pacific
  • 14.4 South America
    • 14.4.1 Brazil
    • 14.4.2 Argentina
    • 14.4.3 Colombia
    • 14.4.4 Chile
    • 14.4.5 Peru
    • 14.4.6 Rest of South America
  • 14.5 Rest of the World (RoW)
    • 14.5.1 Middle East
      • 14.5.1.1 Saudi Arabia
      • 14.5.1.2 United Arab Emirates
      • 14.5.1.3 Qatar
      • 14.5.1.4 Israel
      • 14.5.1.5 Rest of Middle East
    • 14.5.2 Africa
      • 14.5.2.1 South Africa
      • 14.5.2.2 Egypt
      • 14.5.2.3 Morocco
      • 14.5.2.4 Rest of Africa

15 Strategic Market Intelligence

  • 15.1 Industry Value Network and Supply Chain Assessment
  • 15.2 White-Space and Opportunity Mapping
  • 15.3 Product Evolution and Market Life Cycle Analysis
  • 15.4 Channel, Distributor, and Go-to-Market Assessment

16 Industry Developments and Strategic Initiatives

  • 16.1 Mergers and Acquisitions
  • 16.2 Partnerships, Alliances, and Joint Ventures
  • 16.3 New Product Launches and Certifications
  • 16.4 Capacity Expansion and Investments
  • 16.5 Other Strategic Initiatives

17 Company Profiles

  • 17.1 Integra LifeSciences Corporation
  • 17.2 AbbVie Inc. (Allergan Aesthetics)
  • 17.3 LifeNet Health
  • 17.4 MTF Biologics
  • 17.5 Organogenesis Holdings Inc.
  • 17.6 CollPlant Biotechnologies Ltd.
  • 17.7 Matricel GmbH
  • 17.8 Cook Biotech Inc.
  • 17.9 Stryker Corporation
  • 17.10 Smith+Nephew plc
  • 17.11 CorMatrix Cardiovascular, Inc.
  • 17.12 Tissue Regenix Group plc
  • 17.13 Miromatrix Medical Inc.
  • 17.14 AxoGen, Inc.
  • 17.15 Humacyte, Inc.
  • 17.16 Kerecis
  • 17.17 RTI Surgical Holdings, Inc.
  • 17.18 Medtronic plc

List of Tables

  • Table 1 Global Extracellular Matrix Biomaterials Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Extracellular Matrix Biomaterials Market Outlook, By Biomaterial Source (2023-2034) ($MN)
  • Table 3 Global Extracellular Matrix Biomaterials Market Outlook, By Human-Derived (2023-2034) ($MN)
  • Table 4 Global Extracellular Matrix Biomaterials Market Outlook, By Animal-Derived (2023-2034) ($MN)
  • Table 5 Global Extracellular Matrix Biomaterials Market Outlook, By Plant-Derived (2023-2034) ($MN)
  • Table 6 Global Extracellular Matrix Biomaterials Market Outlook, By Microbial-Derived (2023-2034) ($MN)
  • Table 7 Global Extracellular Matrix Biomaterials Market Outlook, By Recombinant and Synthetic (2023-2034) ($MN)
  • Table 8 Global Extracellular Matrix Biomaterials Market Outlook, By ECM Material Type (2023-2034) ($MN)
  • Table 9 Global Extracellular Matrix Biomaterials Market Outlook, By Collagen (2023-2034) ($MN)
  • Table 10 Global Extracellular Matrix Biomaterials Market Outlook, By Elastin (2023-2034) ($MN)
  • Table 11 Global Extracellular Matrix Biomaterials Market Outlook, By Fibronectin (2023-2034) ($MN)
  • Table 12 Global Extracellular Matrix Biomaterials Market Outlook, By Laminin (2023-2034) ($MN)
  • Table 13 Global Extracellular Matrix Biomaterials Market Outlook, By Hyaluronic Acid (2023-2034) ($MN)
  • Table 14 Global Extracellular Matrix Biomaterials Market Outlook, By Fibrin (2023-2034) ($MN)
  • Table 15 Global Extracellular Matrix Biomaterials Market Outlook, By Proteoglycans (2023-2034) ($MN)
  • Table 16 Global Extracellular Matrix Biomaterials Market Outlook, By Decellularized ECM (2023-2034) ($MN)
  • Table 17 Global Extracellular Matrix Biomaterials Market Outlook, By Material Form (2023-2034) ($MN)
  • Table 18 Global Extracellular Matrix Biomaterials Market Outlook, By Hydrogels (2023-2034) ($MN)
  • Table 19 Global Extracellular Matrix Biomaterials Market Outlook, By Scaffolds (2023-2034) ($MN)
  • Table 20 Global Extracellular Matrix Biomaterials Market Outlook, By Sheets and Membranes (2023-2034) ($MN)
  • Table 21 Global Extracellular Matrix Biomaterials Market Outlook, By Sponges (2023-2034) ($MN)
  • Table 22 Global Extracellular Matrix Biomaterials Market Outlook, By Films (2023-2034) ($MN)
  • Table 23 Global Extracellular Matrix Biomaterials Market Outlook, By Injectable Biomaterials (2023-2034) ($MN)
  • Table 24 Global Extracellular Matrix Biomaterials Market Outlook, By Microparticles and Nanoparticles (2023-2034) ($MN)
  • Table 25 Global Extracellular Matrix Biomaterials Market Outlook, By Bioinks (2023-2034) ($MN)
  • Table 26 Global Extracellular Matrix Biomaterials Market Outlook, By Scaffold Architecture (2023-2034) ($MN)
  • Table 27 Global Extracellular Matrix Biomaterials Market Outlook, By Porous (2023-2034) ($MN)
  • Table 28 Global Extracellular Matrix Biomaterials Market Outlook, By Fibrous (2023-2034) ($MN)
  • Table 29 Global Extracellular Matrix Biomaterials Market Outlook, By Nanostructured (2023-2034) ($MN)
  • Table 30 Global Extracellular Matrix Biomaterials Market Outlook, By Composite (2023-2034) ($MN)
  • Table 31 Global Extracellular Matrix Biomaterials Market Outlook, By Gradient (2023-2034) ($MN)
  • Table 32 Global Extracellular Matrix Biomaterials Market Outlook, By Functional Properties (2023-2034) ($MN)
  • Table 33 Global Extracellular Matrix Biomaterials Market Outlook, By Cell-Adhesive (2023-2034) ($MN)
  • Table 34 Global Extracellular Matrix Biomaterials Market Outlook, By Cell-Instructive (2023-2034) ($MN)
  • Table 35 Global Extracellular Matrix Biomaterials Market Outlook, By Biodegradable (2023-2034) ($MN)
  • Table 36 Global Extracellular Matrix Biomaterials Market Outlook, By Bioactive (2023-2034) ($MN)
  • Table 37 Global Extracellular Matrix Biomaterials Market Outlook, By Immunomodulatory (2023-2034) ($MN)
  • Table 38 Global Extracellular Matrix Biomaterials Market Outlook, By Angiogenic (2023-2034) ($MN)
  • Table 39 Global Extracellular Matrix Biomaterials Market Outlook, By Osteoinductive (2023-2034) ($MN)
  • Table 40 Global Extracellular Matrix Biomaterials Market Outlook, By Self-Assembling (2023-2034) ($MN)
  • Table 41 Global Extracellular Matrix Biomaterials Market Outlook, By Organ (2023-2034) ($MN)
  • Table 42 Global Extracellular Matrix Biomaterials Market Outlook, By Skin (2023-2034) ($MN)
  • Table 43 Global Extracellular Matrix Biomaterials Market Outlook, By Bone and Cartilage (2023-2034) ($MN)
  • Table 44 Global Extracellular Matrix Biomaterials Market Outlook, By Cardiovascular (2023-2034) ($MN)
  • Table 45 Global Extracellular Matrix Biomaterials Market Outlook, By Neural (2023-2034) ($MN)
  • Table 46 Global Extracellular Matrix Biomaterials Market Outlook, By Muscle (2023-2034) ($MN)
  • Table 47 Global Extracellular Matrix Biomaterials Market Outlook, By Liver (2023-2034) ($MN)
  • Table 48 Global Extracellular Matrix Biomaterials Market Outlook, By Kidney (2023-2034) ($MN)
  • Table 49 Global Extracellular Matrix Biomaterials Market Outlook, By Lung (2023-2034) ($MN)
  • Table 50 Global Extracellular Matrix Biomaterials Market Outlook, By Corneal and Ocular (2023-2034) ($MN)
  • Table 51 Global Extracellular Matrix Biomaterials Market Outlook, By Dental and Oral (2023-2034) ($MN)
  • Table 52 Global Extracellular Matrix Biomaterials Market Outlook, By Processing Technology (2023-2034) ($MN)
  • Table 53 Global Extracellular Matrix Biomaterials Market Outlook, By Decellularization (2023-2034) ($MN)
  • Table 54 Global Extracellular Matrix Biomaterials Market Outlook, By Solubilization (2023-2034) ($MN)
  • Table 55 Global Extracellular Matrix Biomaterials Market Outlook, By Crosslinking (2023-2034) ($MN)
  • Table 56 Global Extracellular Matrix Biomaterials Market Outlook, By Freeze-Drying (2023-2034) ($MN)
  • Table 57 Global Extracellular Matrix Biomaterials Market Outlook, By Electrospinning (2023-2034) ($MN)
  • Table 58 Global Extracellular Matrix Biomaterials Market Outlook, By 3D Bioprinting (2023-2034) ($MN)
  • Table 59 Global Extracellular Matrix Biomaterials Market Outlook, By Gelation (2023-2034) ($MN)
  • Table 60 Global Extracellular Matrix Biomaterials Market Outlook, By Chemical Modification (2023-2034) ($MN)
  • Table 61 Global Extracellular Matrix Biomaterials Market Outlook, By Enzymatic Processing (2023-2034) ($MN)
  • Table 62 Global Extracellular Matrix Biomaterials Market Outlook, By Application (2023-2034) ($MN)
  • Table 63 Global Extracellular Matrix Biomaterials Market Outlook, By Tissue Engineering (2023-2034) ($MN)
  • Table 64 Global Extracellular Matrix Biomaterials Market Outlook, By Wound Healing (2023-2034) ($MN)
  • Table 65 Global Extracellular Matrix Biomaterials Market Outlook, By Drug Delivery (2023-2034) ($MN)
  • Table 66 Global Extracellular Matrix Biomaterials Market Outlook, By Cell Therapy (2023-2034) ($MN)
  • Table 67 Global Extracellular Matrix Biomaterials Market Outlook, By Gene Delivery (2023-2034) ($MN)
  • Table 68 Global Extracellular Matrix Biomaterials Market Outlook, By 3D Cell Culture (2023-2034) ($MN)
  • Table 69 Global Extracellular Matrix Biomaterials Market Outlook, By Organoid Development (2023-2034) ($MN)
  • Table 70 Global Extracellular Matrix Biomaterials Market Outlook, By Disease Modeling (2023-2034) ($MN)
  • Table 71 Global Extracellular Matrix Biomaterials Market Outlook, By Drug Screening and Toxicology (2023-2034) ($MN)
  • Table 72 Global Extracellular Matrix Biomaterials Market Outlook, By End User (2023-2034) ($MN)
  • Table 73 Global Extracellular Matrix Biomaterials Market Outlook, By Pharmaceutical and Biotechnology Companies (2023-2034) ($MN)
  • Table 74 Global Extracellular Matrix Biomaterials Market Outlook, By Medical Device Companies (2023-2034) ($MN)
  • Table 75 Global Extracellular Matrix Biomaterials Market Outlook, By Hospitals and Clinics (2023-2034) ($MN)
  • Table 76 Global Extracellular Matrix Biomaterials Market Outlook, By Academic and Research Institutions (2023-2034) ($MN)
  • Table 77 Global Extracellular Matrix Biomaterials Market Outlook, By Contract Research Organizations (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.